Semaglutide (Ozempic) vs Semaglutide (Wegovy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: July 2028 · NCT07073053 (registry estimate)
Reported efficacy
Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)
Result source: NCT04560998
Semaglutide (Wegovy)
Marketed by Novo Nordisk
NCT03574597 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 17,604 participants and a hard cardiovascular event primary endpoint. The primary endpoint was met: 569 participants receiving semaglutide versus 701 receiving placebo experienced a qualifying event, with a hazard ratio of 0.80 (95% CI 0.72–0.89; p<0.0001).
Reported efficacy
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)
Result source: NCT03574597
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Semaglutide (Ozempic) | Semaglutide (Wegovy) |
|---|---|---|
| LDL-C, % change | —Not reported | —Not reported |
| Non-HDL-C, % change | —Not reported | —Not reported |
| ApoB, % change | —Not reported | —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Wegovy)
- —Not reported
Non-HDL-C, % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Wegovy)
- —Not reported
ApoB, % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Wegovy)
- —Not reported
Lp(a), % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Wegovy)
- —Not reported
3-point MACE (% with event)
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Wegovy)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Semaglutide (Ozempic): 3 of 4 rows · Semaglutide (Wegovy): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Ozempic) |
|---|---|
| Dropout rate | 7.6%a NCT04560998 · Phase 3 |
| Discontinued due to AEs | —a NCT04560998 · Phase 3 |
| Serious AEs | 18.7%a NCT04560998 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Ozempic)
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Semaglutide (Ozempic)'s landscape · Semaglutide (Wegovy)'s landscape